The DOI matches its Crossref record; 276 of the 278 references it cites were found in a registry or an index.
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
Open accessPublished version of a preprint
Abstract
Adaptive designs (ADs) allow pre-planned changes to an ongoing trial without compromising the validity of conclusions and it is essential to distinguish pre-planned from unplanned changes that may also occur. The reporting of ADs in randomised trials is inconsistent and needs improving. Incompletely reported AD randomised trials are difficult to reproduce and are hard to interpret and synthesise. This consequently hampers their ability to inform practice as well as future research and contributes to research waste. Better transparency and adequate reporting will enable the potential benefits of ADs to be realised. This extension to the Consolidated Standards Of Reporting Trials (CONSORT) 2010 statement was developed to enhance the reporting of randomised AD clinical trials. We developed an Adaptive designs CONSORT Extension (ACE) guideline through a two-stage Delphi process with input from multidisciplinary key stakeholders in clinical trials research in the public and private sectors from 21 countries, followed by a consensus meeting. Members of the CONSORT Group were involved during the development process. The paper presents the ACE checklists for AD randomised trial reports and abstracts, as well as an explanation with examples to aid the application of the guideline. The ACE checklist comprises seven new items, nine modified items, six unchanged items for which additional explanatory text clarifies further considerations for ADs, and 20 unchanged items not requiring further explanatory text. The ACE abstract checklist has one new item, one modified item, one unchanged item with additional explanatory text for ADs, and 15 unchanged items not requiring further explanatory text. The intention is to enhance transparency and improve reporting of AD randomised trials to improve the interpretability of their results and reproducibility of their methods, results and inference. We also hope indirectly to facilitate the much-needed knowledge transfer of innovative trial designs to maximise their potential benefits. In order to encourage its wide dissemination this article is freely accessible on the BMJ and Trials journal websites. “To maximise the benefit to society, you need to not just do research but do it well” Douglas G Altman
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Adapted from Steg et al. [182]](/paper-figures/7a5ba43922b94815b6414eed1fd37d47/the-adaptive-designs-consort-extension-ace-statement-a-checklist-with-figure-1.jpg)
![Fig. 2 Redrawn from Gilson et al. [260] Reused in accordance with the terms of Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). No changes to the original figure were made](/paper-figures/c4967b9adaa2452aa490488db9787f70/the-adaptive-designs-consort-extension-ace-statement-a-checklist-with-figure-2.jpg)
![Fig. 3 Redrawn from Pallmann et al. [22] Reused in accordance with the terms of Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). No changes to the original figure were made](/paper-figures/af5adb783a4949fe8b065e0c7ac619ff/the-adaptive-designs-consort-extension-ace-statement-a-checklist-with-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Extensions to CONSORT have been developed to tackle the methodological issues associated with reporting different types of trial designs, data, and interventions.”
From CONSORT 2025 statement: Updated guideline for reporting randomised trials (2025) · cites this paper as [33]
Experimental — accuracy not yet measuredIn the citing paper
“Extensions to CONSORT have been developed to tackle the methodological issues associated with reporting different types of trial designs, data, and interventions.”
From CONSORT 2025 statement: updated guideline for reporting randomised trials (2025) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Self-citationMoher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
Nogueira, R. G., Jadhav, A. P., Haussen, D. C., Bonafé, A., Budzik, R. F., Bhuva, P., Yavagal, D. R., Ribó, M., Cognard, C., Hanel, R. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706442 · Cited by 5,667
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
Self-citationConsort 2010 statement: extension to cluster randomised trials
Campbell, M. K., Piaggio, G., Elbourne, D. R., Altman, D. G., & for the CONSORT Group (2012) · BMJ · doi:10.1136/bmj.e5661 · Cited by 3,510
Self-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Self-citationAn improved Bonferroni procedure for multiple tests of significance
SIMES, R. J. (1986) · Biometrika · doi:10.1093/biomet/73.3.751 · Cited by 2,396
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 2,007
Self-citationGroup sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593
Self-citationSystematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
Dwan, K., Altman, D. G., Arnaiz, J. A., Bloom, J., Chan, A.-W., Cronin, E., Decullier, E., Easterbrook, P. J., Von Elm, E., Gamble, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003081 · Cited by 1,546
Self-citation(2002) · The Lancet · doi:10.1016/s0140-6736(02)08651-8 · Cited by 1,457
Guidance for Developers of Health Research Reporting Guidelines
Moher, D., Schulz, K. F., Simera, I., & Altman, D. G. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000217 · Cited by 1,437
Self-citationOn closed testing procedures with special reference to ordered analysis of variance
Marcus, R., Peritz, E., & Gabriel, K. R. (1976) · Biometrika · doi:10.1093/biomet/63.3.655 · Cited by 1,417
Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer
Kelsen, D. P., Ginsberg, R., Pajak, T. F., Sheahan, D. G., Gunderson, L., Mortimer, J., Estes, N., Haller, D. G., Ajani, J., Kocha, W., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812313392704 · Cited by 1,343
Group Sequential Methods with Applications to Clinical Trials
Jennison, C., & Turnbull, B. W. (1999) · Chapman & Hall/CRC eBooks · doi:10.1201/9780367805326 · Cited by 1,339
Moher, D., Jones, A., Lepage, L., & for the CONSORT Group (2001) · JAMA · doi:10.1001/jama.285.15.1992 · Cited by 1,027
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A. S., Stewart, D. J., Hicks, M. E., Erasmus, J. J., Gupta, S. K., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 898
Plint, A. C., Moher, D., Morrison, A., Schulz, K., Altman, D. G., Hill, C., & Gaboury, I. (2006) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00557.x · Cited by 872
Self-citationEvaluation of Experiments with Adaptive Interim Analyses
Bauer, P., & Kohne, K. (1994) · Biometrics · doi:10.2307/2533441 · Cited by 869
Adaptive designs in clinical trials: why use them, and how to run and report them
Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., Holmes, J., Mander, A. P., Odondi, L., Sydes, M. R., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1017-7 · Cited by 829 · cited 10×
“Notably, classification of ADs in the literature is inconsistent [13, 22], while the scope and complexity of trial adaptations and underpinning statistical methods continues to broaden [18, 20, 106].”
BackgroundInfluentialSelf-citationA Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma
Léauté-Labrèze, C., Hoeger, P. H., Mazereeuw‐Hautier, J., Guibaud, L., Baselga, E., Pošiūnas, G., Phillips, R., Cáceres, H., López‐Gutiérrez, J. C., Ballona, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1404710 · Cited by 794
CONSORT 2010 statement: extension to randomised crossover trials
Dwan, K., Li, T., Altman, D. G., & Elbourne, D. (2019) · BMJ · doi:10.1136/bmj.l4378 · Cited by 785
Self-citationI-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C. C., Gj, K., Hylton, N., Berry, D., & Esserman, L. J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 767
Hopewell, S., Clarke, M., Moher, D., Wager, E., Middleton, P., Altman, D. G., Schulz, K. F., & and the CONSORT Group (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050020 · Cited by 674
Self-citationThe Design and Analysis of Sequential Clinical Trials.
Harrington, D. T., & Whitehead, J. (1985) · Journal of the American Statistical Association · doi:10.2307/2288093 · Cited by 637
Bassler, D. (2010) · JAMA · doi:10.1001/jama.2010.310 · Cited by 613
Adaptive Sample Size Calculations in Group Sequential Trials
Lehmacher, W., & Wassmer, G. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.01286.x · Cited by 599
Avery, K. N. L., Williamson, P. R., Gamble, C., O'Connell Francischetto, E., Metcalfe, C., Davidson, P., Williams, H., & Blazeby, J. M. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013537 · Cited by 575
Modification of Sample Size in Group Sequential Clinical Trials
Cui, L., Hung, H. M. J., & Wang, S. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00853.x · Cited by 574
Statistical Principles for Clinical Trials
Kay, R. (1998) · Journal of International Medical Research · doi:10.1177/030006059802600201 · Cited by 573
Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease
Thadhani, R., Appelbaum, E. A., Pritchett, Y., Chang, Y., Wenger, J., Tamez, H. E., Bhan, I., Agarwal, R., Zoccali, C., Wanner, C., et al. (2012) · JAMA · doi:10.1001/jama.2012.120 · Cited by 572
Biomarkers and surrogate endpoints in clinical trials
Fleming, T. R., & Powers, J. H. (2012) · Statistics in Medicine · doi:10.1002/sim.5403 · Cited by 559
Designed Extension of Studies Based on Conditional Power
Proschan, M. A., & Hunsberger, S. (1995) · Biometrics · doi:10.2307/2533262 · Cited by 536
Self-citationGuidelines for the Content of Statistical Analysis Plans in Clinical Trials
Gamble, C., Krishan, A., Stocken, D., Lewis, S., Juszczak, E., Doré, C., Williamson, P. R., Altman, D. G., Montgomery, A., Lim, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.18556 · Cited by 536
Self-citationThe Design and Analysis of Sequential Clinical Trials.
Whitehead, J. (1997) · Biometrics · doi:10.2307/2533535 · Cited by 524
Testing for baseline balance in clinical trials
Senn, S. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131703 · Cited by 503
Adaptive design methods in clinical trials–a review
Chow, S.-C., & Chang, M. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-11 · Cited by 482 · cited 4×
“This may include deviations from pre-planned adaptations and decision rules [15, 66], as well as changes to timing and frequency of interim analyses.”
BackgroundInfluentialCONSORT for reporting randomised trials in journal and conference abstracts
Hopewell, S., Clarke, M., Moher, D., Wager, E., Middleton, P., Altman, D. G., & Schulz, K. F. (2008) · The Lancet · doi:10.1016/s0140-6736(07)61835-2 · Cited by 458
Self-citationBerry, S. M., Connor, J. T., & Lewis, R. J. (2015) · JAMA · doi:10.1001/jama.2015.2316 · Cited by 379
de Boer, M. R., Waterlander, W. E., Kuijper, L. D., Steenhuis, I. H., & Twisk, J. W. (2015) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/s12966-015-0162-z · Cited by 370
Adaptive increase in sample size when interim results are promising: a practical guide with examples
Mehta, C. R., & Pocock, S. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4102 · Cited by 367
Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease: Indacaterol Versus Tiotropium
Donohue, J. F., Fogarty, C. M., Lötvall, J. O., Mahler, D. A., Worth, H., Yorgancıoğlu, A., Iqbal, A., Swales, J., Owen, R. J., Higgins, M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200910-1500oc · Cited by 357
Stochastically curtailed tests in long–term clinical trials
Lan, K. K. G., Simon, R. M., & Halperin, M. (1982) · Sequential Analysis · doi:10.1080/07474948208836014 · Cited by 356
The Theory of Response‐Adaptive Randomization in Clinical Trials
Hu, F., & Rosenberger, W. F. (2006) · Wiley series in probability and statistics · doi:10.1002/047005588x · Cited by 352
Comparability of Randomised Groups
Altman, D. G. (1985) · Journal of the Royal Statistical Society Series D (The Statistician) · doi:10.2307/2987510 · Cited by 329
Self-citationReporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement
Juszczak, E., Altman, D. G., Hopewell, S., & Schulz, K. (2019) · JAMA · doi:10.1001/jama.2019.3087 · Cited by 324
Self-citationAdaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group
Gallo, P. P., Chuang‐Stein, C., Dragalin, V., Gaydos, B. L., Krams, M., & Pinheiro, J. C. (2006) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400600614742 · Cited by 323
Efficiencies of platform clinical trials: A vision of the future
Saville, B. R., & Berry, S. M. (2016) · Clinical Trials · doi:10.1177/1740774515626362 · Cited by 318
Monitoring clinical trials: Conditional or predictive power?
Spiegelhalter, D. J., Freedman, L. S., & Blackburn, P. R. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90003-6 · Cited by 317
Combining different phases in the development of medical treatments within a single trial
Bauer, P., & Kieser, M. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990730)18:14 · Cited by 289
Stahl, M., Walz, M. K., Riera‐Knorrenschild, J., Stuschke, M., Sandermann, A., Bitzer, M., Wilke, H., & Budach, W. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.04.027 · Cited by 284
MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial
Zajicek, J., Hobart, J. C., Slade, A. L., Barnes, D., & Mattison, P. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302468 · Cited by 277
Bretz, F., Schmidli, H., König, F., Racine, A., & Maurer, W. (2006) · Biometrical Journal · doi:10.1002/bimj.200510232 · Cited by 273
Adaptive designs for confirmatory clinical trials
Bretz, F., König, F., Brannath, W., Glimm, E., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3538 · Cited by 265
Adaptive trial designs: a review of barriers and opportunities
Kairalla, J. A., Coffey, C. S., Thomann, M. A., & Muller, K. E. (2012) · Trials · doi:10.1186/1745-6215-13-145 · Cited by 249
Group sequential designs using a family of type I error probability spending functions
Hwang, I. K., Shih, W. J., & de Cani, J. S. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091207 · Cited by 247
Testing and estimation in flexible group sequential designs with adaptive treatment selection
Posch, M., König, F., Branson, M., Brannath, W., Dunger‐Baldauf, C., & Bauer, P. (2005) · Statistics in Medicine · doi:10.1002/sim.2389 · Cited by 244 · cited 6×
“Using the methods of Posch and Bauer [64], as agreed upon during the special protocol assessment process, a p-value was obtained for comparison of each dose to the placebo arm from the stage I data, and an additional p-value was obtained for comparison of the optimal dose to the placebo arm from the independent data g…”
MethodInfluentialSample size re-estimation without unblinding for normally distributed outcomes with unknown variance
Gould, A. L., & Shih, W. J. (1992) · Communication in Statistics- Theory and Methods · doi:10.1080/03610929208830947 · Cited by 240
COMPare: a prospective cohort study correcting and monitoring 58 misreported trials in real time
Goldacre, B., Drysdale, H., Dale, A., Milosevic, I., Slade, E., Hartley, P., Marston, C., Powell-Smith, A., Heneghan, C., & Mahtani, K. R. (2019) · Trials · doi:10.1186/s13063-019-3173-2 · Cited by 233
Twenty‐five years of confirmatory adaptive designs: opportunities and pitfalls
Bauer, P., Bretz, F., Dragalin, V., König, F., & Wassmer, G. (2015) · Statistics in Medicine · doi:10.1002/sim.6472 · Cited by 231
A review of methods for futility stopping based on conditional power
Lachin, J. M. (2005) · Statistics in Medicine · doi:10.1002/sim.2151 · Cited by 228
Parameter Estimation Following Group Sequential Hypothesis Testing
Emerson, S. S., & Fleming, T. R. (1990) · Biometrika · doi:10.1093/biomet/77.4.875 · Cited by 225
Jenkins, M. A., Stone, A. M., & Jennison, C. (2010) · Pharmaceutical Statistics · doi:10.1002/pst.472 · Cited by 214
Jennison, C., & Turnbull, B. W. (1999) · Chapman & Hall/CRC machine learning & pattern recognition/Chapman & Hall/CRC machine learning & pattern recognition series · doi:10.1201/9781584888581 · Cited by 212
Sample Size Recalculation in Internal Pilot Study Designs: A Review
Friede, T., & Kieser, M. (2006) · Biometrical Journal · doi:10.1002/bimj.200510238 · Cited by 205
The Theory of Response-Adaptive Randomization in Clinical Trials
Hu, F., & Rosenberger, W. F. (2006) · Cited by 201
Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology
Brannath, W., Zuber, E., Branson, M., Bretz, F., Gallo, P. P., Posch, M., & Racine-Poon, A. (2009) · Statistics in Medicine · doi:10.1002/sim.3559 · Cited by 200
Tröger, W., Galun, D. A., Reif, M., Schumann, A., Stanković, N., & Milicevic, M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.043 · Cited by 199
Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov
Bothwell, L. E., Avorn, J., Khan, N. F., & Kesselheim, A. S. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-018320 · Cited by 199 · cited 1×
“In summary, ADs are used in a relatively low proportion of trials, although their use is steadily increasing in both the public and private sectors [114 – 116], and they are frequently considered at the design stage [27].”
BackgroundCook, J. A., Julious, S. A., Sones, W., Hampson, L. V., Hewitt, C., Berlin, J. A., Ashby, D., Emsley, R., Fergusson, D. A., Walters, S. J., et al. (2018) · Trials · doi:10.1186/s13063-018-2884-0 · Cited by 197 · cited 1×
“Criteria for claiming overall evidence (such as based on the probability of the treatment effect being above a certain value, targeted treatment effect of interest, and threshold for statistical significance [174, 175]); 4.”
Self-citationAdaptive assignment versus balanced randomization in clinical trials: A decision analysis
Berry, D. A., & Eick, S. G. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140302 · Cited by 196
Ivers, N. M., Taljaard, M., Dixon, S., Bennett, C., McRae, A., Taleban, J., Skea, Z., Brehaut, J. C., Boruch, R. F., Eccles, M. P., et al. (2011) · BMJ · doi:10.1136/bmj.d5886 · Cited by 193
Brannath, W., Burger, H. U., Glimm, E., Stallard, N., Vandemeulebroecke, M., & Wassmer, G. (2010) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2010.514453 · Cited by 193
Statistical Monitoring of Clinical Trials: a Unified Approach
Chernick, M. R. (2007) · Technometrics · doi:10.1198/tech.2007.s479 · Cited by 190
Adaptive Designs for Randomized Trials in Public Health
Brown, C. H., Ten Have, T. R., Jo, B., Dagne, G., Wyman, P. A., Muthén, B., & Gibbons, R. D. (2009) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.031308.100223 · Cited by 184
Key design considerations for adaptive clinical trials: a primer for clinicians
Thorlund, K., Haggstrom, J., Park, J. J., & Mills, E. J. (2018) · BMJ · doi:10.1136/bmj.k698 · Cited by 182
Sydes, M. R., Parmar, M., Mason, M. D., Clarke, N. W., Amos, C. L., Anderson, J., Bono, J. S. D., Dearnaley, D. P., Dwyer, J., Green, C., et al. (2012) · Trials · doi:10.1186/1745-6215-13-168 · Cited by 175
Self-citationAdaptive Modifications of Hypotheses After an Interim Analysis
Hommel, G. (2001) · Biometrical Journal · doi:10.1002/1521-4036(200109)43:5 · Cited by 170
A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection
Magirr, D., Jaki, T., & Whitehead, J. (2012) · Biometrika · doi:10.1093/biomet/ass002 · Cited by 162
Self-citationAvoidable waste of research related to inadequate methods in clinical trials
Yordanov, Y., Dechartres, A., Porcher, R., Boutron, I., Altman, D. G., & Ravaud, P. (2015) · BMJ · doi:10.1136/bmj.h809 · Cited by 161
Self-citationPractical problems in interim analyses, with particular regard to estimation
Pocock, S., & Hughes, M. D. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90059-7 · Cited by 160
Design of Experiments: Ranking and Selection
Santner, T. J., & Tamhane, A. C. (1984) · Cited by 157
Adaptive Two Stage Designs and the Conditional Error Function
Posch, M., & Bauer, P. (1999) · Biometrical Journal · doi:10.1002/(sici)1521-4036(199910)41:6 · Cited by 153
Heatley, G. J., Sood, P., Goldstein, D. J., Uriel, N. Y., Cleveland, J. C., Middlebrook, D., & Mehra, M. R. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.01.021 · Cited by 151
Estimands in clinical trials – broadening the perspective
Akacha, M., Bretz, F., & Ruberg, S. J. (2016) · Statistics in Medicine · doi:10.1002/sim.7033 · Cited by 150
Cook, J. A., Julious, S. A., Sones, W., Hampson, L. V., Hewitt, C., Berlin, J. A., Ashby, D., Emsley, R., Fergusson, D. A., Walters, S. J., et al. (2018) · BMJ · doi:10.1136/bmj.k3750 · Cited by 148
Self-citationSpeeding up the Evaluation of New Agents in Cancer
Parmar, M., Barthel, F. M.-S., Sydes, M. R., Langley, R. E., Kaplan, R. S., Eisenhauer, E. A., Brady, M. F., James, N. D., Bookman, M. A., Swart, A. M., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn267 · Cited by 144 · cited 1×
“Evaluating multiple treatments in one trial allowing for early selection of promising treatments or dropping futile or unsafe treatments [53 – 55].”
BackgroundSelf-citationPredictive Probability Early Termination Plans For Phase II Clinical Trials
Herson, J. (1979) · Biometrics · doi:10.2307/2530109 · Cited by 143
Adaptive Designs: Terminology and Classification
Dragalin, V. (2006) · Drug Information Journal · doi:10.1177/216847900604000408 · Cited by 142
Statistical Consideration of Adaptive Methods in Clinical Development
Chow, S., Chang, M., & Pong, A. (2005) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-200062277 · Cited by 136
Wason, J. M. S., & Trippa, L. (2014) · Statistics in Medicine · doi:10.1002/sim.6086 · Cited by 136
Self-citationBiomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Antoniou, M., Jorgensen, A., & Kolamunnage‐Dona, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149803 · Cited by 135
Jin, Y., Sanger, N., Shams, I., Luo, C., Shahid, H., Li, G., Bhatt, M., Zielinski, L., Bantoto, B., Wang, M., et al. (2018) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s155103 · Cited by 134
Adaptive Dunnett tests for treatment selection
König, F., Brannath, W., Bretz, F., & Posch, M. (2007) · Statistics in Medicine · doi:10.1002/sim.3048 · Cited by 130
Stopping rules and estimation problems in clinical trials
Hughes, M. D., & Pocock, S. (1988) · Statistics in Medicine · doi:10.1002/sim.4780071204 · Cited by 128
Optimal design of multi‐arm multi‐stage trials
Wason, J. M. S., & Jaki, T. (2012) · Statistics in Medicine · doi:10.1002/sim.5513 · Cited by 127
Self-citationJames, N. D., Sydes, M. R., Mason, M. D., Clarke, N. W., Anderson, J., Dearnaley, D. P., Dwyer, J., Jovic, G., Ritchie, A. W., Russell, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70088-8 · Cited by 123
Ondra, T., Dmitrienko, A. A., Friede, T., Graf, A. C., Miller, F., Stallard, N., & Posch, M. (2015) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2015.1092034 · Cited by 122
Barrington, P., Chien, J. Y., Showalter, H. D. H., Schneck, K., Cui, S., Tibaldi, F., Ellis, B., & Hardy, T. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01364.x · Cited by 120
Estimating a treatment effect in survival studies in which patients switch treatment
Branson, M., & Whitehead, J. (2002) · Statistics in Medicine · doi:10.1002/sim.1219 · Cited by 120
Evaluation of Intravenous Peramivir for Treatment of Influenza in Hospitalized Patients
de Jong, M. D., Ison, M. G., Monto, A. S., Metev, H., Clark, C. L., O’Neil, B. J., Elder, J., McCullough, A. J., Collis, P., & Sheridan, W. P. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu632 · Cited by 117
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design
Barnes, P. J., Pocock, S., MAGNUSSEN, H., Iqbal, A., Krämer, B., Higgins, M., & Lawrence, D. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.01.003 · Cited by 116
Self-citationGood Practices for Adaptive Clinical Trials in Pharmaceutical Product Development
Gaydos, B. L., Anderson, K. M., Berry, D. A., Burnham, N., Chuang‐Stein, C., Dudinak, J., Fardipour, P., Gallo, P. P., Givens, S., Lewis, R. J., et al. (2009) · Drug Information Journal · doi:10.1177/009286150904300503 · Cited by 113
Some recommendations for multi-arm multi-stage trials
Wason, J. M. S., Magirr, D., Law, M. W.-M., & Jaki, T. (2012) · Statistical Methods in Medical Research · doi:10.1177/0962280212465498 · Cited by 112
Self-citationThe reassessment of trial perspectives from interim data—a critical view
Bauer, P., & König, F. (2005) · Statistics in Medicine · doi:10.1002/sim.2180 · Cited by 110
PLANNING AND REVISING THE SAMPLE SIZE FOR A TRIAL
Gould, A. L. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140922 · Cited by 108
The Design and Analysis of Sequential Clinical Trials (2nd ed.).
Lachenbruch, P. A., & Whitehead, J. (1993) · Journal of the American Statistical Association · doi:10.2307/2290372 · Cited by 108
Sample Size Reestimation: A Review and Recommendations
Chuang‐Stein, C., Anderson, K. M., Gallo, P. P., & Collins, S. H. (2006) · Drug Information Journal · doi:10.1177/216847900604000413 · Cited by 107
Adaptive designs undertaken in clinical research: a review of registered clinical trials
Hatfield, I., Allison, A., Flight, L., Julious, S. A., & Dimairo, M. (2016) · Trials · doi:10.1186/s13063-016-1273-9 · Cited by 107
Self-citationGroup Sequential Tests for Delayed Responses (with discussion)
Hampson, L. V., & Jennison, C. (2012) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/j.1467-9868.2012.01030.x · Cited by 104
Khalil, E. A. G., Weldegebreal, T., Younis, B. M., Omollo, R., Musa, A. M., Hailu, W., Abuzaid, A. A., Dorlo, T. P. C., Hurissa, Z., Yifru, S., et al. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002613 · Cited by 101
Critical concepts in adaptive clinical trials
Park, J., Thorlund, K., & Mills, E. J. (2018) · Clinical Epidemiology · doi:10.2147/clep.s156708 · Cited by 100
A comparison of methods for adaptive sample size adjustment
Friede, T., & Kieser, M. (2001) · Statistics in Medicine · doi:10.1002/sim.972 · Cited by 99
Selection and bias—Two hostile brothers
Bauer, P., König, F., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3716 · Cited by 99
Giles, F. J., Kantarjian, H. M., Cortes, J. E., Garcia‐Manero, G., Verstovšek, S., Faderl, S. H., Thomas, D. A., Ferrajoli, A., O'Brien, S. M., Wathen, J. K., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.016 · Cited by 99
Elsäßer, A., Regnström, J., Vetter, T., König, F., Hemmings, R. J., Greco, M., Papaluca‐Amati, M., & Posch, M. (2014) · Trials · doi:10.1186/1745-6215-15-383 · Cited by 96
Flexible Sample Size Considerations Using Information-Based Interim Monitoring
Mehta, C. R., & Tsiatis, A. A. (2001) · Drug Information Journal · doi:10.1177/009286150103500407 · Cited by 94 · cited 6×
“Bayesian GSD with futility early stopping; frequency and timing of interim analyses; adaptation decision-making criteria; criteria for claiming treatment benefit “ We adopted a group-sequential Bayesian design [182] with three stages, of 40 patients each (in total), and two interim analyses after 40 and 80 randomised…”
MethodInfluentialWhen and How Can Endpoints Be Changed after Initiation of a Randomized Clinical Trial
Evans, S. R. (2007) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0020018 · Cited by 92
Overrunning and underrunning in sequential clinical trials
Whitehead, J. (1992) · Controlled Clinical Trials · doi:10.1016/0197-2456(92)90017-t · Cited by 92
Parmar, M., Sydes, M. R., Cafferty, F. H., Choodari‐Oskooei, B., Langley, R. E., Brown, L. C., Phillips, P. P. J., Spears, M. R., Rowley, S., Kaplan, R. S., et al. (2017) · Clinical Trials · doi:10.1177/1740774517725697 · Cited by 91
Self-citationContinuous Infusion of Clonidine in Ventilated Newborns and Infants
Hünseler, C., Balling, G., Röhlig, C., Blickheuser, R., Trieschmann, U., Lieser, U., Dohna‐Schwake, C., Gebauer, C. M., Möller, O., Hering, F., et al. (2014) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000000151 · Cited by 90
Benefits, challenges and obstacles of adaptive clinical trial designs
Chow, S., & Corey, R. G. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-79 · Cited by 88
Monitoring Clinical Trials Based on Predictive Probability of Significance
Choi, S. C., & Pepple, P. A. (1989) · Biometrics · doi:10.2307/2532056 · Cited by 88
Frequentist evaluation of group sequential clinical trial designs
Emerson, S. S., Kittelson, J. M., & Gillen, D. L. (2007) · Statistics in Medicine · doi:10.1002/sim.2901 · Cited by 87
Clinical trial designs incorporating predictive biomarkers
Renfro, L. A., Mallick, H., An, M., Sargent, D. J., & Mandrekar, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.12.008 · Cited by 85
Implementing Adaptive Designs: Logistical and Operational Considerations
Quinlan, J., & Krams, M. (2006) · Drug Information Journal · doi:10.1177/216847900604000409 · Cited by 84
No solution yet for combining two independent studies in the presence of heterogeneity
Gonnermann, A., Framke, T., Großhennig, A., & Koch, A. (2015) · Statistics in Medicine · doi:10.1002/sim.6473 · Cited by 83
Estimation in flexible two stage designs
Brannath, W., König, F., & Bauer, P. (2005) · Statistics in Medicine · doi:10.1002/sim.2258 · Cited by 83
Supplementary Analysis at the Conclusion of a Sequential Clinical Trial
Whitehead, J. (1986) · Biometrics · doi:10.2307/2531197 · Cited by 80
Estimands and Their Role in Clinical Trials
Akacha, M., Bretz, F., Ohlssen, D. I., Rosenkranz, G., & Schmidli, H. (2017) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2017.1302358 · Cited by 79
Mehta, C. R., Liu, L., & Theuer, C. P. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy464 · Cited by 78
Stopping clinical trials early for benefit: impact on estimation
Freidlin, B., & Korn, E. L. (2009) · Clinical Trials · doi:10.1177/1740774509102310 · Cited by 76
Coffey, C. S., & Kairalla, J. A. (2008) · Drugs in R&D · doi:10.2165/00126839-200809040-00003 · Cited by 75
A practical guide to Bayesian group sequential designs
Gsponer, T., Gerber, F., Bornkamp, B., Ohlssen, D. I., Vandemeulebroecke, M., & Schmidli, H. (2013) · Pharmaceutical Statistics · doi:10.1002/pst.1593 · Cited by 74
A Bayesian adaptive design for clinical trials in rare diseases
Williamson, S. F., Jacko, P., Villar, S. S., & Jaki, T. (2016) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2016.09.006 · Cited by 74
Self-citationSkrivanek, Z., Gaydos, B. L., Chien, J. Y., Geiger, M. J., Heathman, M. A., Berry, S. M., Anderson, J. H., Forst, T. M., Miličević, Z., & Berry, D. A. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12305 · Cited by 73
Coffey, C. S., Levin, B. L., Clark, C., Timmerman, C., Wittes, J. T., Gilbert, P. R., & Harris, S. (2012) · Clinical Trials · doi:10.1177/1740774512461859 · Cited by 73
Steg, P. G. (2013) · JAMA · doi:10.1001/jama.2013.277165 · Cited by 73
Maintaining confidentiality of interim data to enhance trial integrity and credibility
Fleming, T. R., SHARPLES, K. J., McCall, J. L., Moore, A., Rodgers, A., & Stewart, R. (2008) · Clinical Trials · doi:10.1177/1740774508089459 · Cited by 71
Quinlan, J., Gaydos, B. L., Maca, J., & Krams, M. (2010) · Clinical Trials · doi:10.1177/1740774510361542 · Cited by 70
Challenging Issues in Clinical Trial Design
Pocock, S., Clayton, T. C., & Stone, G. W. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.051 · Cited by 69
MiRoR network, Blanco, D., Biggane, A. M., & Cobo, E. (2018) · Trials · doi:10.1186/s13063-018-2475-0 · Cited by 68
Adaptive Design: Results of 2012 Survey on Perception and Use
Morgan, C. C., Huyck, S. B., Jenkins, M. A., Chen, L., Bedding, A. W., Coffey, C. S., Gaydos, B. L., & Wathen, J. K. (2014) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479014522468 · Cited by 67 · cited 1×
“methods [29, 78, 107] and interest in their application by researchers and research funders [26, 28, 108].”
BackgroundAdaptive sample size modification in clinical trials: start small then ask for more?
Jennison, C., & Turnbull, B. W. (2015) · Statistics in Medicine · doi:10.1002/sim.6575 · Cited by 63
Chataway, J., Nicholas, R. S., Todd, S., Miller, D. H., Parsons, N., Valdés‐Márquez, E., Stallard, N., & Friede, T. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510382129 · Cited by 63
Self-citationConfidentiality and Trial Integrity Issues for Adaptive Designs
Gallo, P. P. (2006) · Drug Information Journal · doi:10.1177/216847900604000410 · Cited by 62
Sample size recalculation for binary data in internal pilot study designs
Friede, T., & Kieser, M. (2004) · Pharmaceutical Statistics · doi:10.1002/pst.140 · Cited by 62
Stevely, A. K., Dimairo, M., Todd, S., Julious, S. A., Nicholl, J. P., Hind, D., & Cooper, C. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141104 · Cited by 60
Self-citationThe pragmatic clinical trial in a learning health care system
Lewis, R. (2016) · Clinical Trials · doi:10.1177/1740774516655097 · Cited by 60
Effect of Levocarnitine vs Placebo as an Adjunctive Treatment for Septic Shock
Jones, A. E., Puskarich, M. A., Shapiro, N. I., Guirgis, F. W., Runyon, M. S., Adams, J. Y., Sherwin, R. L., Arnold, R., Roberts, B. W., Kurz, M. C., et al. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6076 · Cited by 60
The advantages and disadvantages of adaptive designs for clinical trials
Bauer, P., & Brannath, W. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03023-5 · Cited by 59
An overview of the design and conduct of the BATTLE trials.
Liu, S., & Lee, J. J. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.06.07 · Cited by 58
A seamless Phase IIB/III adaptive outcome trial: Design rationale and implementation challenges
Chen, Y. H. J., Gesser, R., & Luxembourg, A. T. (2014) · Clinical Trials · doi:10.1177/1740774514552110 · Cited by 57 · cited 1×
“Investigating multiple research objectives that are traditionally examined in distinct trial phases, in one trial under a single protocol [74 – 76].”
A multi-stage drop-the-losers design for multi-arm clinical trials
Wason, J. M. S., Stallard, N., Bowden, J., & Jennison, C. (2014) · Statistical Methods in Medical Research · doi:10.1177/0962280214550759 · Cited by 57
Self-citationBayesian clinical trial designs
Jansen, J. O., Pallmann, P., MacLennan, G., & Campbell, M. (2017) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000001638 · Cited by 56
Self-citationJanackovic, K., & Puljak, L. (2018) · Trials · doi:10.1186/s13063-018-2976-x · Cited by 56
Dimairo, M., Coates, E. J., Pallmann, P., Todd, S., Julious, S. A., Jaki, T., Wason, J. M. S., Mander, A., Weir, C. J., König, F., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1196-2 · Cited by 56
Self-citationWhen is a seamless study desirable? Case studies from different pharmaceutical sponsors
Cuffe, R. L., Lawrence, D., Stone, A. M., & Vandemeulebroecke, M. (2014) · Pharmaceutical Statistics · doi:10.1002/pst.1622 · Cited by 55
Self-citationDwan, K., Kirkham, J. J., Williamson, P. R., & Gamble, C. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002709 · Cited by 55
Dimairo, M., Boote, J. D., Julious, S. A., Nicholl, J. P., & Todd, S. (2015) · Trials · doi:10.1186/s13063-015-0958-9 · Cited by 55
Self-citationOptimal multistage designs for randomised clinical trials with continuous outcomes
Wason, J. M. S., Mander, A., & Thompson, S. G. (2011) · Statistics in Medicine · doi:10.1002/sim.4421 · Cited by 53 · cited 1×
“These may encompass the maximum sample size, expected sample sizes under certain scenarios, probabilities of identifying beneficial treatments if they exist, and probabilities of making false positive claims of evidence [172, 173].”
BackgroundSelf-citationMacArthur, R. D., Hawkins, T., Brown, S. J., LaMarca, A., Clay, P. G., Barrett, A. C., Bortey, E. B., Paterson, C. A., Golden, P. L., & Forbes, W. P. (2013) · HIV Clinical Trials · doi:10.1310/hct1406-261 · Cited by 53
Application of Adaptive Designs – a Review
Bauer, P., & Einfalt, J. (2006) · Biometrical Journal · doi:10.1002/bimj.200510204 · Cited by 53
Alternative Views On Setting Clinical Trial Futility Criteria
Gallo, P. P., Mao, L., & Shih, V. H. (2014) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2014.932285 · Cited by 53
Design and Monitoring of Multi-Arm Multi-Stage Clinical Trials
Ghosh, P., Liu, L., Senchaudhuri, P., Gao, P., & Mehta, C. R. (2017) · Biometrics · doi:10.1111/biom.12687 · Cited by 53
Mistry, P., Dunn, J., & Marshall, A. (2017) · BMC Medical Research Methodology · doi:10.1186/s12874-017-0393-6 · Cited by 53
Outcome reporting bias in randomized-controlled trials investigating antipsychotic drugs
Lancee, M., Lemmens, C. M. C., Kahn, R. S., Vinkers, C. H., & Luykx, J. J. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.203 · Cited by 53
Benefit–risk assessment: the use of clinical utility index
Ouellet, D. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740330903499265 · Cited by 51
CBER’s Experience With Adaptive Design Clinical Trials
Lin, M. J., Lee, S., Zhen, B., Scott, J., Horne, A. D., Solomon, G., & Russek‐Cohen, E. (2015) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479015604181 · Cited by 51
Self-citationFlexible sequential designs for multi‐arm clinical trials
Magirr, D., Stallard, N., & Jaki, T. (2014) · Statistics in Medicine · doi:10.1002/sim.6183 · Cited by 50
Self-citationAdaptive Design in Clinical Research: Issues, Opportunities, and Recommendations
Chang, M., Chow, S., & Pong, A. (2006) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400600609718 · Cited by 49
Wang, H., Rosner, G. L., & Goodman, S. N. (2016) · Clinical Trials · doi:10.1177/1740774516649595 · Cited by 49
Vitamin D Receptor Activation and Left Ventricular Hypertrophy in Advanced Kidney Disease
Thadhani, R., Appelbaum, E. A., Chang, Y., Pritchett, Y., Bhan, I., Agarwal, R., Zoccali, C., Wanner, C., Lloyd‐Jones, D. M., Cannata-Andía, J. B., et al. (2011) · American Journal of Nephrology · doi:10.1159/000323551 · Cited by 48
Exact Confidence Bounds Following Adaptive Group Sequential Tests
Brannath, W., Mehta, C. R., & Posch, M. (2008) · Biometrics · doi:10.1111/j.1541-0420.2008.01101.x · Cited by 48
Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice
Cohen, D. R., Todd, S., Gregory, W. M., & Brown, J. M. (2015) · Trials · doi:10.1186/s13063-015-0697-y · Cited by 48
Self-citationLorch, U., O’Kane, M., & Täubel, J. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-84 · Cited by 47
Collignon, O., König, F., Koch, A., Hemmings, R. J., Pétavy, F., Saint-Raymond, A., Papaluca‐Amati, M., & Posch, M. (2018) · Trials · doi:10.1186/s13063-018-3012-x · Cited by 47
Self-citationOn Stopping a Randomized Clinical Trial for Futility
Herson, J., Buyse, M. E., & Wittes, J. T. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0140-7_5 · Cited by 46
Whitehead, J., & Jaki, T. (2008) · Statistics in Medicine · doi:10.1002/sim.3508 · Cited by 46 · cited 1×
“The critical values for recommending that a treatment is taken to further testing at the interim and final analyses (2.782 and 2.086) have been chosen to guarantee these properties using a method described by Magirr et al. [177], generalising the approach of Whitehead and Jaki [178].”
MethodInfluentialSelf-citationA Bayesian adaptive design for biomarker trials with linked treatments
Wason, J. M. S., Abraham, J., Baird, R. D., Gournaris, I., Vallier, A.-L., Brenton, J. D., Earl, H. M., & Mander, A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.278 · Cited by 45 · cited 1×
“…drop-the-loser with SSR [99]; inferentially seamless phase 2/3 AD with hypotheses selection [77] or population enrichment [100]; biomarker-stratified with RAR [101]; adaptive platform trials where arms can be added or stopped early [19, 24, 102]. reporting can help address these concerns [22, 27].”
BackgroundSelf-citationStatistical inference for cancer trials with treatment switching
Shao, J., Chang, M., & Chow, S. (2005) · Statistics in Medicine · doi:10.1002/sim.2128 · Cited by 45
Repeated confidence intervals for adaptive group sequential trials
Mehta, C. R., Bauer, P., Posch, M., & Brannath, W. (2007) · Statistics in Medicine · doi:10.1002/sim.3062 · Cited by 45
Wang, S.-J., & Hung, H. (2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2013.09.008 · Cited by 45
Exact inference for adaptive group sequential designs
Gao, P., Liu, L., & Mehta, C. R. (2013) · Statistics in Medicine · doi:10.1002/sim.5847 · Cited by 44
On the Independence of Data Monitoring Committee in Adaptive Design Clinical Trials
Chow, S., Corey, R., & Lin, M. J. (2012) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2012.676536 · Cited by 44
Multi-arm clinical trials with treatment selection: what can be gained and at what price?
Jaki, T. (2015) · Clinical Investigation · doi:10.4155/cli.15.13 · Cited by 43
Self-citationFernandes, R. M., van der Lee, J. H., & Offringa, M. (2009) · BMC Pediatrics · doi:10.1186/1471-2431-9-77 · Cited by 43 · cited 1×
“However, these methods are rarely used or reported and the implications are unclear [45, 209, 235].”
Lewis, R. J., Angus, D. C., Laterre, P., Kjølbye, A. L., van der Meulen, E., Blemings, A., Graves, T., Russell, J. A., Carlsen, J. E., Jacobsen, K., et al. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201708-669sd · Cited by 43
Statistical testing for baseline differences between randomised groups is not meaningful
Harvey, L. A. (2018) · Spinal Cord · doi:10.1038/s41393-018-0203-y · Cited by 43
Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group
Phillips, A. J., Keene, O. N., & on behalf of the PSI Adaptive Design Expert Group (2006) · Pharmaceutical Statistics · doi:10.1002/pst.206 · Cited by 42
Self-citationWalter, S. D., Guyatt, G. H., Bassler, D., Briel, M., Ramsay, T., & Han, H. (2019) · Statistics in Medicine · doi:10.1002/sim.8142 · Cited by 41
Confirmatory Clinical Trials with an Adaptive Design
Koch, A. (2006) · Biometrical Journal · doi:10.1002/bimj.200510239 · Cited by 40
Geiger, M. J., Skrivanek, Z., Gaydos, B. L., Chien, J. Y., Berry, S. M., Berry, D. A., & Anderson, J. H. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600610 · Cited by 40
Meurer, W. J., Legocki, L. J., Mawocha, S., Frederiksen, S. M., Guetterman, T. C., Barsan, W. G., Lewis, R. J., Berry, D. A., & Fetters, M. D. (2016) · Trials · doi:10.1186/s13063-016-1493-z · Cited by 40
Self-citationBačkonja, M., Williams, L. J., Miao, X., Katz, N. P., & Chen, C. (2017) · Pain · doi:10.1097/j.pain.0000000000000983 · Cited by 40
Wason, J. M. S., & Mander, A. (2012) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2010.528104 · Cited by 37
Self-citation
Research works printed but not linked: 4
- Detry MA, Lewis RJ, Broglio KR, et al. Standards for the design, conduct, and evaluation of adaptive randomized clinical trials. 2012. https://www.pcori.org/assets/Standards-for-the-Design-Conduct-and-Evaluation-of-Adaptive-Randomized-Clinical-Trials.pdf.
- Hack N, Brannath W. Estimation in adaptive group sequential trials; 2011.
- Vandemeulebroecke M. An investigation of two-stage tests. Stat Sin. 2006;16:933–51.
- Wagenmakers E-J, Gronau QF, Stefan A, et al. A Bayesian perspective on the proposed FDA guidelines for adaptive clinical trials. 2018. https://www.bayesianspectacles.org/a-bayesian-perspective-on-the-proposed-fda-guidelines-for-adaptive-clinical-trials/.
Cited by
Sorted by citations
CONSORT 2025 statement: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081123 · Cited by 1,195
Self-citationCONSORT 2025 statement: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00672-5 · Cited by 510
Self-citationHopewell, S., Chan, A., Collins, P. G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · JAMA · doi:10.1001/jama.2025.4347 · Cited by 444
Self-citationCONSORT 2025 statement: updated guideline for reporting randomized trials
Hopewell, S., Chan, A., Collins, P. G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03635-5 · Cited by 332
“Examples of extensions for trial designs include recommendations for adaptive designs 33 , cluster trials 34 , crossover trials 35 , early phase trials 36 , factorial trials 37 , non-inferiority and equivalence trials 38 , pragmatic trials 39 , multi-arm trials 40 , n-of-1 trials 41 , pilot and…”
Self-citationLuchini, C., Veronese, N., Nottegar, A., Shin, J. I., Gentile, G., Granziol, U., Soysal, P., Alexinschi, O., Smith, L., & Solmi, M. (2020) · Pharmaceutical Statistics · doi:10.1002/pst.2068 · Cited by 249
“transparency and improving the report of adaptive-design randomized trials, to increase both the interpretability of their results and reproducibility of their methods, results, and inference.(25)”
Method
Metadata
- Authors
- Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., Nicholl, J. P., Coates, E., Biggs, K., Hamasaki, T., Proschan, M. A., Scott, J. A., Ando, Y., Hind, D., Altman, D. G., on behalf of the ACE Consensus Group, Dimairo, M., Hamasaki, T., Todd, S., Weir, C. J., Mander, A. P., Wason, J., Koenig, F., Julious, S. A., Hind, D., Nicholl, J., Altman, D. G., Meurer, W. J., Cates, C., Sydes, M., Jemiai, Y., Ashby, D., Yap, C., Waldron-Lynch, F., Roger, J., Marsh, J., Collignon, O., Lawrence, D. J., Bunce, C., Parke, T., Gazzard, G., Coates, E., Walton, M. K., Hopewell, S., Pallmann, P., Jaki, T., Biggs, K., Proschan, M. A., Scott, J. A., & Ando, Y.
- Affiliations
- University of Sheffield (GB)
- University of Edinburgh (GB)
- Newcastle University (GB)
- Cardiff University (GB)
- ORCID
- Venue
- Trials
- Published
- 2020-06-17
- Volume
- 21
- Issue
- 1
- Pages
- 528-528
- ISSN
- 1745-6215 (ISSN-L)
- PMC
- PMC7298968
- OpenAlex
- W3000741148
- Cited by
- 58
- References
- 278
- Citations by year
- 2026: 1 · 2025: 17 · 2024: 14 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 5
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Trials (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Lancaster EPrints (Lancaster University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Cancer Research UK (16895)
- National Institute for Health and Care Research (DRF-2012-05-182, SRF-2015-08-001)
- Department of Health and Social Care
- University of Sheffield
- Medical Research Council (NIHR-SRF-2015-08-001, MR/L004933/1, MR/L004933/2, MR/N028171/1, MC_UU_12023/24, MR/L004933/1-R/N/P/B1)
- NIHR Academy (SRF-2015-08-001)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Social Sciences › Sociology and Political Science › Delphi Technique in Research
- Keywords
- adaptive design, CONSORT extension, reporting guidelines, randomised trials, research waste
- MeSH terms
- Delphi Technique, Humans, Periodicals as Topic, Publishing, Quality Control, Research Design, Reproducibility of Results, Randomized Controlled Trials as Topic, Guidelines as Topic, Consensus, Checklist
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review